Article Per Year (5 Year)
p-Index From 2020 - 2025
0.751
P-Index
This Author published in this journals
All Journal Jurnal Belantara Asian Journal of Health Research Journal of Professional Education
Wulandhari
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Education Environmental Science Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : Asian Journal of Health Research

 1 
Systematic Review & Meta-Analysis Triple Inhaler Therapy Outperforms Dual Therapy in Moderate to Severe COPD: A Meta-Analysis of 11,477 Patients from 4 Randomized Controlled Trials Shows Improved Lung Function, Reduced Exacerbations, and Comparable Safety Profile Albab, Chabib Fachry; Habibah, Almas Talida; Wulandhari; Murteza, Faiq; Mas'udi, Achmad Fayyad
Asian Journal of Health Research Vol. 4 No. 1 (2025): Volume 4 No 1 (April) 2025
Publisher : Ikatan Dokter Indonesia Wilayah Jawa Timur

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55561/ajhr.v4i1.224

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) continues to be one of the most prevalent health conditions globally. Treatment strategies for COPD are often tailored to disease severity, beginning with single therapy and advancing to dual or triple therapy as needed. However, limited randomized controlled trials (RCTs) have explored the comparative impact of dual and triple inhaler therapies on clinical outcomes and exacerbation frequencies. Our meta-analysis aims to evaluate the effectiveness and safety of triple and double medication in moderate and severe COPD patients.    Material and Methods: A comprehensive exploration of databases was conducted to identify RCTs comparing triple and dual inhaler therapies. For binary outcomes, the pooled RR or OR was calculated; we also used weighted MD to analyze continuous outcomes, both with high CI (95%).    Results: The meta-analysis included four RCTs involving 13,574 patients, of whom 67.92% were male. Triple inhaler therapy proves lung function improvements significantly, evidenced by an increase in FEV1 (MD: 0.06; 95% CI: 0.01–0.11; p=0.02). It showed significant association with a exacerbations reduction in both moderate and severe one (RR: 0.76; 95% CI: 0.72–0.81; p<0.000001). No notable differences in adverse events were observed between combination of triple and double medication (OR: 0.99; 95% CI: 0.90–1.10; p=0.85).    Conclusion: Triple inhaler medication proves more effective than double medication in moderate and severe COPD patients, enhancing lung function and lowering exacerbation rates without a significant increase in adverse effects.
Co-Authors Afif Bintoro Albab, Chabib Fachry Damayanti, Inggar Habibah, Almas Talida Mas'udi, Achmad Fayyad Mufidah , Lailatul MUFIDAH, LAILATUL Muhammad Rifqi Hariri Murteza, Faiq